Yawen Wang

Zhongshan, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

NR5A2 (located on chromosome 1q32) inhibits ferroptosis and promotes drug resistance by regulating phospholipid remodeling in multiple myeloma.

NR5A2 (located on chromosome 1q32) inhibits ferroptosis and promotes drug resistance by regulating phospholipid remodeling in multiple myeloma.

Journal: International journal of biological sciences
Published: March 03, 2025

The role of proliferating stem-like plasma cells in relapsed or refractory multiple myeloma: Insights from single-cell RNA sequencing and proteomic analysis.

The role of proliferating stem-like plasma cells in relapsed or refractory multiple myeloma: Insights from single-cell RNA sequencing and proteomic analysis.

Journal: British journal of haematology
Published: December 01, 2023

Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China.

Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China.

Journal: Hematology (Amsterdam, Netherlands)
Published: November 29, 2023

Update on the outcome of M-protein screening program of multiple myeloma in China: A 7-year cohort study.

Update on the outcome of M-protein screening program of multiple myeloma in China: A 7-year cohort study.

Journal: Cancer medicine
Published: June 06, 2023

Thrombosis events in Chinese patients with newly diagnosed multiple myeloma.

Thrombosis events in Chinese patients with newly diagnosed multiple myeloma.

Journal: Clinical and experimental medicine
Published: February 26, 2023

The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center.

The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center.

Journal: Cancer medicine
Published: November 09, 2022

Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.

Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.

Journal: Annals of hematology
Published: September 17, 2022

The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.

The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.

Journal: Cancer
Published: July 20, 2022
Showing 1-8 of 8

Last Updated: 09/26/2026